Your fast, high-signal look at everything that moved biotech, medtech, and pharma today. The BioMed Nexus Daily Update delivers the most important regulatory moves, trial readouts, deals, and industry developments in one concise, easy-to-scan report. Updated every weekday morning.
The M&A machine that defined Q1 has carried directly into Q2 without missing a beat. Gilead Sciences announced a definitive agreement to acquire Munich-based Tubulis
The biggest oral obesity event of the year happened last week, and it landed faster than anyone expected. The FDA approved Lilly’s Foundayo (orforglipron) on
This is the most consequential trade action to hit the pharmaceutical industry in modern history. President Trump signed a Section 232 proclamation on April 2
Q1 2026 is in the books, and the numbers tell the story of an industry in active transformation. Biopharma spent approximately $46.8 billion acquiring 19
Novo Nordisk made two very different kinds of news on the same day, and together they reveal exactly where the company stands in the GLP-1
Tuesday was the biggest single-day M&A event in biopharma since the start of 2026. Eli Lilly committed up to $7.8 billion to acquire Centessa Pharmaceuticals
Two very different signals about where pharma is headed landed on the same day. Eli Lilly announced the largest AI drug discovery deal in the
The weekend delivered on both fronts. Rocket Pharma finally landed FDA approval for Kresladi after a two-year journey, marking the first gene therapy for severe
Wednesday told two dramatically different stories about the distance between clinical data and stock price. Sarepta Therapeutics surged 35% after reporting the first clinical results
The big pharma M&A machine keeps running. Merck announced a $6.7 billion acquisition of Terns Pharmaceuticals on Wednesday, adding TERN-701—an oral allosteric BCR::ABL1 inhibitor for
